1. Analyst View 2. Research Methodology 3. Hemophilia: An Overview 4. Market Dynamics 4.1 Drivers 4.1.1 Development of Inhibitors in Hemophilia Patients 4.1.2 Rising Healthcare Expenditure 4.1.3 Increasing Awareness 4.1.4 Rising Life Expectancy 4.1.5 Grants and Tax Credits 4.1.6 Shorter Development Timeline and Orphan Drug Exclusivity (ODE) 4.2 Challenges 4.2.1 Manufacturing Difficulties 4.2.2 Low Switching Rate 4.3 Opportunities 4.3.1 Incessant Launch of New Generation of Recombinant Factor Products 4.3.2 Growing Geriatric Population 5. Global Hemophilia Therapeutics Market Outlook 2022 6. Major Products in Hemophilia Therapeutics Market 6.1 Advate 6.2 NovoSeven/NovoSeven RT 6.3 Kogenate/Kovaltry 6.4 Feiba 6.5 BeneFix 6.6 ReFacto AF/Xyntha 6.7 Eloctate/Elocta 6.8 Alprolix 6.9 Alphanate 6.10 Rixubis 6.11 NovoEight 6.12 Adynovate/Adynovi 7. Market Segmentation by Type of Hemophilia 7.1 Hemophilia A 7.2 Hemophilia B 7.3 Others 8. Market Segmentation by Type of Treatment 8.1 On-Demand 8.2 Prophylaxis 9. Market Segmentation by Type of Therapy 9.1 Replacement Therapy 9.2 Immune Tolerance Induction Therapy 10. Market Segmentation by Geography 10.1 North America 10.2 Europe 10.3 Asia-Pacific 11. Gene Therapy - Future of Hemophilia Treatment 12. Trends & Developments 13. Mergers & Acquisitions 14. Pipeline Analysis 15. Company Profiles 15.1 Novo Nordisk A/S 15.2 Pfizer Inc. 15.3 F. Hoffmann-La Roche Ltd. 15.4 Bayer AG 15.5 Shire plc 15.6 CSL Limited 15.7 Octapharma AG 15.8 Grifols International SA 15.9 Swedish Orphan Biovitrum AB 15.10 Alnylam Pharmaceuticals, Inc. List of Figures: Figure 3-1: Hemophilia Genetic Inheritance Figure 4-1: Global - Population 60 Years or Above (Billion), 2015, 2030 & 2050 Figure 5-1: Global - Hemophilia Therapeutics Market (Billion US$), 2016 & 2022 Figure 6-1: Global - Sales of Advate (Billion US$), 2015 & 2016 Figure 6-2: Global - Sales of NovoSeven/NovoSeven RT (Billion US$), 2015 & 2016 Figure 6-3: Global - Sales of Kogenate/Kovaltry (Billion US$), 2015 & 2016 Figure 6-4: Global - Sales of Feiba (Billion US$), 2015 & 2016 Figure 6-5: Global - Sales of BeneFix (Billion US$), 2015 & 2016 Figure 6-6: Global - Sales of ReFacto AF/Xyntha (Billion US$), 2015 & 2016 Figure 6-7: Global - Sales of Eloctate/Elocta (Billion US$), 2015 & 2016 Figure 6-8: Global - Sales of Alprolix (Billion US$), 2015 & 2016 Figure 6-9: Global - Sales of Alphanate (Billion US$), 2015 & 2016 Figure 6-10: Global - Sales of Rixubis (Billion US$), 2015 & 2016 Figure 6-11: Global - Sales of NovoEight (Billion US$), 2015 & 2016 Figure 6-12: Global - Sales of Adynovate/Adynovi (Billion US$), 2015 & 2016 Figure 7-1: Global - Hemophilia Therapeutics Market Breakup by Type of Hemophilia (%), 2016 Figure 7-2: Global - Hemophilia A Therapeutics Market (Billion US$), 2016 & 2022 Figure 7-3: Global - Hemophilia B Therapeutics Market (Billion US$), 2016 & 2022 Figure 7-4: Global - Other Hemophilia Therapeutics Market (Billion US$), 2016 & 2022 Figure 8-1: Global - Hemophilia Therapeutics Market Breakup by Type of Treatment (%), 2016 Figure 8-2: Global - On-Demand Hemophilia Therapeutics Market (Billion US$), 2016 & 2022 Figure 8-3: Global - Prophylaxis Hemophilia Therapeutics Market (Billion US$), 2016 & 2022 Figure 9-1: Global - Hemophilia Therapeutics Market Breakup by Type of Therapy (%), 2016 Figure 9-2: Global - Replacement Therapy Market for Hemophilia (Billion US$), 2016 & 2022 Figure 9-3: Global – Immune Tolerance Induction Therapy Market for Hemophilia (Billion US$), 2016 & 2022 Figure 10-1: Global - Hemophilia Therapeutics Market Breakup by Geography (%), 2016 Figure 10-2: North America - Hemophilia Therapeutics Market (Billion US$), 2016 & 2022 Figure 10-3: North America - Population 60 Years or Above (Million), 2015, 2030 & 2050 51 Figure 10-4: Europe - Hemophilia Therapeutics Market (Billion US$), 2016 & 2022 Figure 10-5: Asia-Pacific - Hemophilia Therapeutics Market (Billion US$), 2016 & 2022 Figure 11-1: Gene Therapy Using Adenovirus Vector Figure 15-1: Novo Nordisk A/S - Breakup of Sales by Business Segment (%), 2016 Figure 15-2: Novo Nordisk A/S - Breakup of Sales by Geography (%), 2016 Figure 15-3: Pfizer Inc. - Breakup of Revenue by Business Segment (%), 2016 Figure 15-4: Pfizer Inc. - Breakup of Revenue by Geography (%), 2016 Figure 15-5: F. Hoffmann-La Roche Ltd. - Breakup of Sales by Business Segment (%), 2016 Figure 15-6: Bayer AG - Breakup of Sales by Business Segment (%), 2016 Figure 15-7: Bayer AG - Breakup of Sales by Geography (%), 2016 Figure 15-8: Shire plc - Breakup of Revenue by Geography (%), 2016 Figure 15-9: CSL Limited - Breakup of Revenue by Business Segment (%), FY 2016 Figure 15-10: CSL Limited - Breakup of Revenue by Geography (%), FY 2016 Figure 15-11: Grifols International SA - Breakup of Revenue by Business Segment (%), 2016 Figure 15-12: Grifols International SA - Breakup of Revenue by Geography (%), 2016 Figure 15-13: Swedish Orphan Biovitrum AB - Breakup of Revenue by Product Category (%), 2016 Figure 15-14: Swedish Orphan Biovitrum AB - Breakup of Revenue by Geography (%), 2016 List of Tables: Table 13-1: Mergers, Acquisitions & Collaborations in Hemophilia Therapeutics Market (2014-2017) Table 14-1: Global - Hemophilia Products Pipeline Analysis Table 15-1: Novo Nordisk A/S - Key Financials (Billion US$), 2014-2016 Table 15-2: Novo Nordisk A/S - Marketed Hemophilia Products Table 15-3: Novo Nordisk A/S - Hemophilia Products in Pipeline Table 15-4: Pfizer Inc. - Key Financials (Billion US$), 2014-2016 Table 15-5: Pfizer Inc. - Marketed Hemophilia Products Table 15-6: Pfizer Inc. - Hemophilia Products in Pipeline Table 15-7: F. Hoffmann-La Roche Ltd. - Key Financials (Billion US$), 2014-2016 Table 15-8: F. Hoffmann-La Roche Ltd. - Hemophilia Products in Pipeline Table 15-9: Bayer AG - Key Financials (Billion US$), 2014-2016 Table 15-10: Bayer AG - Marketed Hemophilia Products Table 15-11: Bayer AG - Hemophilia Products in Pipeline Table 15-12: Shire plc - Key Financials (Billion US$), 2014-2016 Table 15-13: Shire plc - Marketed Hemophilia Products Table 15-14: Shire plc - Hemophilia Products in Pipeline Table 15-15: CSL Limited - Key Financials (Billion US$), FY 2014-FY 2016 Table 15-16: CSL Limited - Marketed Hemophilia Products Table 15-17: CSL Limited - Hemophilia Products in Pipeline Table 15-18: Octapharma AG - Key Financials (Billion US$), 2014-2016 Table 15-19: Octapharma AG - Marketed Hemophilia Products Table 15-20: Octapharma AG - Hemophilia Products in Pipeline Table 15-21: Grifols International SA - Key Financials (Billion US$), 2014-2016 Table 15-22: Grifols International SA - Marketed Hemophilia Products Table 15-23: Grifols International SA - Hemophilia Products in Pipeline Table 15-24: Swedish Orphan Biovitrum AB - Key Financials (Billion US$), 2014-2016 Table 15-25: Swedish Orphan Biovitrum AB - Marketed Hemophilia Products Table 15-26: Swedish Orphan Biovitrum AB - Hemophilia Products in Pipeline Table 15-27: Alnylam Pharmaceuticals, Inc. - Hemophilia Products in Pipeline